Juliachs, M.; Pujals, M.; Bellio, C.; Meo-Evoli, N.; Duran, J.M.; Zamora, E.; Parés, M.; Suñol, A.; Méndez, O.; Sánchez-Pla, A.;
et al. Circulating SOD2 Is a Candidate Response Biomarker for Neoadjuvant Therapy in Breast Cancer. Cancers 2022, 14, 3858.
https://doi.org/10.3390/cancers14163858
AMA Style
Juliachs M, Pujals M, Bellio C, Meo-Evoli N, Duran JM, Zamora E, Parés M, Suñol A, Méndez O, Sánchez-Pla A,
et al. Circulating SOD2 Is a Candidate Response Biomarker for Neoadjuvant Therapy in Breast Cancer. Cancers. 2022; 14(16):3858.
https://doi.org/10.3390/cancers14163858
Chicago/Turabian Style
Juliachs, Mercè, Mireia Pujals, Chiara Bellio, Nathalie Meo-Evoli, Juan M. Duran, Esther Zamora, Mireia Parés, Anna Suñol, Olga Méndez, Alex Sánchez-Pla,
and et al. 2022. "Circulating SOD2 Is a Candidate Response Biomarker for Neoadjuvant Therapy in Breast Cancer" Cancers 14, no. 16: 3858.
https://doi.org/10.3390/cancers14163858
APA Style
Juliachs, M., Pujals, M., Bellio, C., Meo-Evoli, N., Duran, J. M., Zamora, E., Parés, M., Suñol, A., Méndez, O., Sánchez-Pla, A., Canals, F., Saura, C., & Villanueva, J.
(2022). Circulating SOD2 Is a Candidate Response Biomarker for Neoadjuvant Therapy in Breast Cancer. Cancers, 14(16), 3858.
https://doi.org/10.3390/cancers14163858